[ISVHLD2012]大会主席闻玉梅院士大会概况介绍

StephenW

[ISVHLD2012]大会主席闻玉梅院士大会概况介绍
                 作者:闻玉梅 时间:2012-6-28 17:38:35 点击:28    加入收藏 关键字:ISVHLD2012 治疗性疫苗 HBV母婴传播
                                
               

　　Hepatology Digest: As the President of the ISVHLD 2012 Meeting in Shanghai， could you introduce the meeting to us and perhaps outline some of the highlights of the meeting?
　　《国际肝病》：作为第14届国际病毒性肝炎和肝病大会（ISVHLD 2012）的主席，请你介绍一下这次会议的概况以及亮点？
　　Prof Wen: At this meeting I think we are going to be addressing some new advances， information and challenges and new solutions. In the top level discussions this morning， most of the scientists gave very impressive advice for the coming years on how we are going to manage viral hepatitis and liver diseases including hepatocellular carcinoma. So our theme was being set as new progress， new ideas， new solutions and new challenges.
　　闻玉梅院士：本次会议将介绍一些新的进展、信息和挑战以及新的解决手段。在今天上午的顶级讨论上，大部分科学家就未来如何治疗病毒性肝炎和肝病（包括肝细胞性肝癌）给出了令人印象深刻的建议。因此我们这次会议的主题设定为新进展、新理念、新策略和新挑战。
　　Hepatology Digest: What would you describe as being the newest challenges?
　　《国际肝病》：您认为最新的挑战是什么？
　　Prof Wen: Currently， the perinatal maternal-fetal transmission of HBV is still a big problem. Around 3%-5% of infections in babies could not be prevented by immunization with the vaccine. So it remains a big challenge with such a big population in China; 3% is not a small number of infections. Also with respect to HCC， we need to work on preventing metastasis and recurrence because that is also a big problem. We also need a lot of basic science studies asking why the virus persists and why the host cannot clear the virus and why some will have surgery quite early in the course of disease but the HCC still metastasizes? These are all new challenges.
　　闻院士：目前，HBV母婴传播仍是很大的问题。约有3%-5%的婴儿期感染不能通过疫苗接种预防，在中国这样一个人口众多的国家，这仍是一大问题。3%的感染不是一个小数字。在HCC方面，需要就防治感染和复发进行研究，因为这也是一个大问题。病毒为何持续存在，宿主为何不能清除病毒，为何一些患者在肝癌极早期接受了外科手术却仍发生转移等，这些问题还需要大量的基础研究来回答。这些都是新的挑战。
　　Hepatology Digest: Having the ISVHLD in Shanghai presents an interesting dynamic. HBV and HCV but particularly HBV， are very much a problem and a focus in Asia. But this is an international meeting. Could you comment on how the international study and the situation in Asia are mixing here at this meeting?
　　《国际肝病》：在上海召开本次ISVHLD具有有益的动力作用。HBV和HCV，尤其是HBV，是亚洲非常常见的一个问题，也是研究的焦点，ISVHLD作为一次国际性的会议，在这次盛会上国际研究和亚洲的形势是如何结合的，请您做一点评？
　　Prof Wen: Although we have a lot of patients and carriers in the Asia-Pacific region， we need to have more information and advanced studies that can help. Even small scale clinical trials and basic science studies will encourage interaction and even collaborations in the future. For instance， there is a suggestion that we will have a website and the idea of getting epidemiology and clinical sciences together to educate the public and re-educate the clinicians. This is all very good advice.
　　闻院士：尽管亚太地区有很多患者和携带者，但我们仍需要更多的有价值的信息和前沿研究，即使小规模的临床和基础研究也能促进研究者间的交流甚至未来的合作。比如，有人建议应建立网站，整合流行病学和临床科学，对公众进行教育和对临床医师进行继续教育，这是非常好的建议。
　　Hepatology Digest: There has been a lot of research in China recently. What do you think is the best research coming out of China right now?
　　《国际肝病》：近期中国有很多研究。您认为中国目前产出的最好的研究是什么？
　　Prof Wen: The best research is on vaccines and how to develop vaccines and prevent transmission within the population and also the strategies for blood transfusion control so that we can have safe blood transfusions. At the same time， there are good papers coming from clinical immunology， clinical cohort studies and also basic science studies in interactions between virus and host. The number of publications from China in the major international journals has increased tremendously in recent years.
　　闻院士：最好的研究是疫苗方面的，如何发展疫苗，预防人群中传播，以及控制输血传播的策略从而保证输血安全。同时，也有很好的临床免疫、临床队列研究和病毒与宿主互作方面的基础研究的论文发表。中国在主要国际刊物上发表的论文的数量近年增长迅猛。
　　Hepatology Digest: I hear that your lab has been working on a therapeutic vaccine. Is that correct?
　　《国际肝病》：您的实验室主要研究治疗性疫苗，是吗？
　　Prof Wen: Yes. We have started on a therapeutic vaccination study; first in ducks then in transgender mice and then with approval from the SFDA to do a clinical trial with Phase I， Phase IIA， Phase IIB and Phase III. My colleagues will be presenting some of our data from the Phase III clinical trial on therapeutic vaccination. However， generally， I think therapeutic vaccines are a more difficult approach but we have started to break the ice and we think there will be more therapeutic vaccines for instance， for HCV， tumors and other persistent infections. So we have opened the door to the area of therapeutic vaccines.
　　闻院士：是的，我们已经开始了治疗性疫苗的研究，首先用鸭和转基因鼠开展研究，获得SFDA批准后进行了临床I期、IIA期、IIB期和III期试验。我的同事将会报告治疗性疫苗III期临床试验的一些结果。总的来说，治疗性疫苗研究非常困难，但是我们已经开始打破坚冰，我们认为将会有更多的治疗性疫苗用于HCV、肿瘤和其他持续感染。我们已经打开了通过治疗性疫苗领域的大门。
　　Hepatology Digest: So you are not expecting there to be a therapeutic vaccine that will be useable very soon but working towards something in the future?
　　《国际肝病》：就是说，治疗性疫苗不会在很近期应用于临床，但是您正在朝着这个方面努力？
　　Prof Wen: Once we have confirmed the efficacy and also done some trials with combination therapy， I would predict it is not too far away from being approved and licensed for use; maybe within a couple of years.
　　闻院士：一旦明确了疗效并完成一些联合治疗试验后，我预测应该在不远的将来，可能就是一两年内，疫苗能获批应用于临床。

zzwwtt

非常困难啊~~~~

cwy121

关键在最后一句，前面说中国的研究成果主要在疫苗就知道咱们国家的研究工作做得如何，都是扯淡的。疫苗预防谁不会，可以说在治疗药物的研究方面，中国和西方至少相差15年以上！

yonggan521

时间一次又一次被延后，拿着钱，到底在做些什么呢

国家代表

曾已何时，你是我们期盼的救星

向明天要幸福

不知道真假，第一次看到说三至五年，现在都拖到第六年了，再一两年那就是2014年了